A
0.650
0.00 (0.00%)
| 前收盘价格 | 0.650 |
| 收盘价格 | 0.670 |
| 成交量 | 506,400 |
| 平均成交量 (3个月) | 379,981 |
| 市值 | 60,327,488 |
| 预期市盈率 (P/E Forward) | 14.99 |
| 价格/销量 (P/S) | 0.480 |
| 股市价格/股市净资产 (P/B) | 0.500 |
| 52周波幅 | |
| 利润日期 | 5 May 2025 - 9 May 2025 |
| 营业毛利率 | -17.27% |
| 营业利益率 (TTM) | -27.35% |
| 稀释每股收益 (EPS TTM) | -0.230 |
| 季度收入增长率 (YOY) | -2.40% |
| 总债务/股东权益 (D/E MRQ) | 33.26% |
| 流动比率 (MRQ) | 1.77 |
| 营业现金流 (OCF TTM) | 26.41 M |
| 杠杆自由现金流 (LFCF TTM) | 33.42 M |
| 资产报酬率 (ROA TTM) | -4.53% |
| 股东权益报酬率 (ROE TTM) | -16.66% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看跌 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Assertio Holdings, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
-0.5
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -4.0 |
| 平均 | -0.50 |
|
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 2.07% |
| 机构持股比例 | 29.62% |
| 52周波幅 | ||
| 中 | 3.50 (438.46%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Mar 2025 | 3.50 (438.46%) | 购买 | 0.710 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合